<DOC>
	<DOCNO>NCT00005886</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use tamoxifen LY353381 may fight breast cancer block use estrogen . PURPOSE : This randomized phase I trial study well tamoxifen work biomarkers tumor tissue , compare LY353381 , treat woman newly diagnose breast cancer .</brief_summary>
	<brief_title>Tamoxifen Compared With LY353381 Treating Women With Newly Diagnosed Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether LY353381 hydrochloride tamoxifen administer interval biopsy re-excision alters expression tissue biomarkers relative placebo control postmenopausal woman newly diagnose breast cancer . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . - Phase I : Patients randomize receive either oral LY353381 hydrochloride oral placebo daily . Upon completion phase I , treatment center begin phase II study . - Phase II : Patients randomize receive either oral tamoxifen oral placebo daily . Treatment phase continue 2-6 week ( schedule lumpectomy mastectomy ) absence disease progression unacceptable toxicity . Patients follow 1 2 week surgery . PROJECTED ACCRUAL : A minimum 120 patient ( 60 per treatment phase ) accrue study within 18 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm noninvasive small invasive breast cancer Low intermediate grade ( ductal carcinoma situ , T1 , T2 ) OR Estrogen and/or progesterone receptor positive Largest mass great 5 cm Clustered microcalcifications abnormality allow upper size limit If distinction mass microcalcifications , size 1 lesion Lumpectomy mastectomy must plan 26 week start study No evidence metastases malignancy Hormone receptor status : Estrogen progesterone receptor positive ( unless low intermediate grade tumor ) PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Postmenopausal one following : Prior oophorectomy Over age 50 prior hysterectomy , ovary remain Uterus ovary intact menstrual period 3 month Performance status : Not specify Life expectancy : Not specify Hematopoietic : Platelet count great 100,000/mm^3 Hemoglobin great 10 g/dL Absolute granulocyte count great 1,000/mm^3 Hepatic : Albumin great 3 g/dL Bilirubin le 1.5 mg/dL AST le 100 U/L Alkaline phosphatase le 200 U/L Renal : Creatinine le 1.5 mg/dL Cardiovascular : No history deep vein thrombosis Pulmonary : No prior pulmonary embolus Other : Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 1 year since prior chemotherapy Endocrine therapy : At least 1 year since prior aromatase inhibitor , antiestrogens , LH agonists/antagonists No concurrent hormone replacement therapy oral contraceptive ( time randomization ) Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent treatment malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>